Singapore Medical Group in the pink of health
The Catalist-listed company today has a market capitalisation of over S$200 million, and has been profitable since FY2016.
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
THESE days Singapore Medical Group (SMG) barely resembles the once ailing entity that it was.
In 2013, the Catalist-listed group faced significant headwinds and losses due to the changing medical landscape in Singapore: declining medical tourism, changing economics of healthcare and growing trend of consolidation of medical practices.
The same year, SMG chief executive officer Dr Beng Teck Liang and his partners, including SMG chairman Tony Tan Choon Keat, a founder of Singapore's Parkway Holdings, acquired a controlling shareholding of SMG and set out a three-year plan to rebuild the business.
Copyright SPH Media. All rights reserved.
TRENDING NOW
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
Singaporeans can now buy record amount of yen per Singdollar
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Keppel DC Reit posts 13.2% higher Q1 DPU of S$0.02833 on strong portfolio performance
